Our collaboration partner, Roche Genentech, is applying the TransCon technology to develop anti-vascular endothelial growth factor (anti-VEGF) for the treatment of age-related macular edema (AMD) and other ophthalmic indications.
TransCon anti-VEGF is designed to support up to half-yearly ocular administration frequencies and to provide comparable efficacy to current intravitreal anti-VEGF injections.
Roche Genentech is currently evaluating the safety and efficacy of various TransCon prodrug candidates for intravitreal administration.
Ophthalmic diseases, including neovascular wet AMD, macular edema following retinal vein occlusion and diabetic macular edema, are serious sight-threatening diseases. Without treatment, most patients experience progressive and inevitable vision loss. Anti-VEGF therapies have been transformative in the treatment of these diseases, resulting in patients routinely gaining back significant vision for several years. Lucentis® (ranibizumab) is a leading anti-VEGF drug, and is administered as periodic intravitreal injections. Due to the invasiveness of frequent intravitreal injections, there is a significant unmet medical need for longer acting anti-VEGF therapy.